Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | Biomarkers in ultra low-risk myeloma

Meral Beksac • 24 Jun 2020
EHA 2020
Multiple Myeloma

Meral Beksac, MD, Ankara University, Ankara, Turkey, evaluates biomarkers of response in ultra low-risk multiple myeloma and the development of a genomic score that can be used for prognosis and treatment management. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Meral Beksac

Guidance on managing ocular toxicities associated with belantamab mafodotin in multiple myeloma 1:38
Guidance on managing ocular toxicities associated with belantamab mafodotin in multiple myeloma
Meral Beksac • 17 Sep 2025
Improving CAR T-cell responsiveness and overcoming resistance in multiple myeloma 3:02
Improving CAR T-cell responsiveness and overcoming resistance in multiple myeloma
Meral Beksac • 17 Sep 2025
Strategies to enhance the efficacy of CAR T-cell therapy in multiple myeloma 1:56
Strategies to enhance the efficacy of CAR T-cell therapy in multiple myeloma
Meral Beksac • 17 Sep 2025
Baseline ocular conditions and the risk of ocular events in patients with RRMM treated with belamaf 3:04
Baseline ocular conditions and the risk of ocular events in patients with RRMM treated with belamaf
Meral Beksac • 13 Jun 2025

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals